British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...